J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

 
• By Jessica Merrill
  
pillar
J&J outlined a broad development plan for nipocalimab, which it hopes will be a new pillar brand • Source: Alamy

More from Immunological

More from Therapy Areas